Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates Spanish healthcare company Grifols has teamed up with the US government agencies, including the Biomedical Advanced Research Development Authority (BARDA) and Food and Drug Administration (FDA), to assess the use of plasma therapy for Covid-19.
The company agreed to gather plasma from patients recovered from coronavirus infection, processing it into a hyperimmune globulin.
Plasma collection should support preclinical and clinical studies of hyperimmune globulin therapy for the potential treatment of Covid-19.
Grifols will process plasma into hyperimmune globulin at its facility in Clayton, North Carolina, US. According to the company, the FDA will